Cisapride
Propulsid (cisapride) is a small molecule pharmaceutical. Cisapride was first approved as Propulsid on 1993-07-29. It is used to treat constipation, dyspepsia, gastroesophageal reflux, and gastroparesis in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 4. In addition, it is known to target 5-hydroxytryptamine receptor 7 and potassium voltage-gated channel subfamily H member 2.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| constipation | HP_0002019 | D003248 | K59.0 |
| dyspepsia | EFO_0008533 | D004415 | K30 |
| gastroesophageal reflux | EFO_0003948 | D005764 | K21 |
| gastroparesis | EFO_1000948 | D018589 | K31.84 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
177 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infertility | D007246 | EFO_0000545 | 3 | 5 | 8 | 21 | 14 | 50 | |
| Fertilization in vitro | D005307 | 1 | 2 | 2 | 7 | 5 | 16 | ||
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | 1 | 2 | 4 | 3 | 2 | 10 |
| Female infertility | D007247 | EFO_0008560 | N97 | 1 | 1 | 1 | 3 | 5 | 10 |
| Hypogonadism | D007006 | E23.0 | 1 | 1 | 1 | 3 | 1 | 7 | |
| Kallmann syndrome | D017436 | Orphanet_478 | E23.0 | — | — | — | 4 | 2 | 6 |
| Intracytoplasmic sperm injections | D020554 | — | — | — | 4 | — | 4 | ||
| Embryo transfer | D004624 | — | — | 1 | 1 | 2 | 4 | ||
| Ovarian hyperstimulation syndrome | D016471 | — | — | 1 | 2 | — | 3 | ||
| Fertility | D005298 | — | — | 1 | 1 | — | 2 |
Show 3 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | 1 | 2 | — | 3 | 5 |
| Klinefelter syndrome | D007713 | EFO_1001006 | Q98.0 | — | — | 1 | — | 1 | 2 |
| Covid-19 | D000086382 | U07.1 | — | 1 | 1 | — | — | 2 | |
| Anovulation | D000858 | — | — | 1 | — | — | 1 | ||
| Assisted reproductive techniques | D027724 | — | — | 1 | — | — | 1 | ||
| Embryonic development | D047108 | — | — | 1 | — | — | 1 | ||
| Adenomatous polyps | D018256 | D28 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ovulation induction | D010062 | — | 2 | — | — | 3 | 5 | ||
| Leiomyoma | D007889 | HP_0000131 | D25 | 1 | 1 | — | — | 1 | 2 |
| Primary ovarian insufficiency | D016649 | EFO_0004266 | E28.3 | 1 | 1 | — | — | 1 | 2 |
| Sinusitis | D012852 | EFO_0007486 | J32 | — | 1 | — | — | — | 1 |
| Infections | D007239 | EFO_0000544 | 1 | 1 | — | — | — | 1 | |
| Endometriosis | D004715 | EFO_0001065 | N80 | 1 | 1 | — | — | — | 1 |
| Ectopic pregnancy | D011271 | O00 | 1 | 1 | — | — | — | 1 | |
| Salpingitis | D012488 | N70.91 | 1 | 1 | — | — | — | 1 | |
| Graft vs host disease | D006086 | D89.81 | 1 | 1 | — | — | — | 1 | |
| Endocrine system diseases | D004700 | EFO_0001379 | E34.9 | 1 | 1 | — | — | — | 1 |
Show 5 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | C80 | 1 | — | — | — | — | 1 | |
| Neuroblastoma | D009447 | EFO_0000621 | 1 | — | — | — | — | 1 | |
| Retinal diseases | D012164 | HP_0000479 | H35.9 | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | 1 | — | — | — | — | 1 | ||
| Azoospermia | D053713 | EFO_0000279 | N46.0 | 1 | — | — | — | — | 1 |
| Neurodermatitis | D009450 | L28.0 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pregnancy tests | D011258 | — | — | — | — | 4 | 4 | ||
| Pregnancy rate | D018873 | — | — | — | — | 2 | 2 | ||
| Hiv | D006678 | O98.7 | — | — | — | — | 2 | 2 | |
| Asthma | D001249 | EFO_0000270 | J45 | — | — | — | — | 2 | 2 |
| Reproductive behavior | D043762 | — | — | — | — | 1 | 1 | ||
| Premature obstetric labor | D007752 | O60 | — | — | — | — | 1 | 1 | |
| Eunuchism | D005058 | EFO_0007266 | E29.1 | — | — | — | — | 1 | 1 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | — | — | 1 | 1 |
| Spinal cord injuries | D013119 | EFO_1001919 | — | — | — | — | 1 | 1 | |
| Spondylarthritis | D025241 | — | — | — | — | 1 | 1 |
Show 31 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | CISAPRIDE |
| INN | cisapride |
| Description | Cisapride is the amide resulting from formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with cis-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-amine. It has been used (as its monohydrate or as its tartrate) for the treatment of gastro-oesophageal reflux disease and for non-ulcer dyspepsia, but its propensity to cause cardiac arrhythmias resulted in its complete withdrawal from many countries, including the U.K., and restrictions on its use elsewhere. It has a role as a serotonergic agonist, an anti-ulcer drug and a gastrointestinal drug. It is a member of piperidines, a member of benzamides, a member of monochlorobenzenes, a substituted aniline, an organofluorine compound and an aromatic ether. |
| Classification | Small molecule |
| Drug class | sulpride derivatives and analogs |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC |
Identifiers
| PDB | — |
| CAS-ID | 81098-60-4 |
| RxCUI | 35255 |
| ChEMBL ID | CHEMBL1729 |
| ChEBI ID | — |
| PubChem CID | 6917698 |
| DrugBank | DB00604 |
| UNII ID | UVL329170W (ChemIDplus, GSRS) |
Target
Agency Approved
HTR4
HTR4
Alternate
HTR7
HTR7
KCNH2
KCNH2
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,785 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
181 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more